Biotech News Stock Review
Thursday, January 24, 2013Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 12:57 AM
